Yunqi Capital Backs STAAR Surgical's Q3 Results, Calls for Alcon Merger Termination

Yunqi Capital, a 5.1% shareholder of STAAR Surgical, congratulates the company on strong Q3 results, beating cost guidance and strengthening its cash position. Yunqi reiterates its view that STAAR's operational and financial challenges are temporary and not structural. The company's robust results support Yunqi's opinion that the proposed sale to Alcon should be terminated. Yunqi believes STAAR has trusted products and established sales channels to capitalize on the growing opportunity in China.